Okay. Yeah, sure. That's, again, a great question. I think that the main differences between, for example, say, a tech startup and a biotech startup, I think one would be the capital, right? Because biotech innovation frequently takes years of research and testing before there is a potential for return on capital. Right, whereas the potential for return is much more quicker with a tech startup. I think that's one of the main differences. The second difference is the technology. Because in a tech company, the company usually develops a software. And then you figure out what are the problems where you could apply that software as a solution, whereas in biotech, it's kind of flipped. Because you know what the problem is, the disease is the problem, it is very well established, you have to figure out how to develop a product a drug that addresses this problem or this market. Okay. That's the I think those are the two main differences. The third difference is the regulation. Yes, every industry does have regulations, and there are numerous government agencies enforcing those regulations. But when it comes to biotechnology, regulation is the law and FDA is a big enforcer of that, right? And the difference is that in the tech industry, monitoring is not a big step in the process. Another thing would be barriers to entry, right? Because when you think of tech entrepreneurs, you think of like young, vibrant people, Harvard dropouts, or something that working out of garages and like coming up with these disruptive technologies. Whereas when you think about biotechs, you need someone with a strong scientific background. This usually entails five to six years of PhD, maybe four to five years of postdoc after that. So there is a you know, with tech, there is lower barrier to entry, I would say, I think it was a patent. I think patents are much more integral for biotechs. Because you know, if you hold the key patents is impossible for another competitor to get into your market space until that patent expires. Whereas with tech, you know, it's kind of different. I think, once you establish a market, it's very easy for competitors to come in and copycat and chip away at your share of that market. So I think that's another major difference between biotech and tech startups. But you know, so another thing is that, about 20 years ago, if you asked anyone what a biotech is, they would have defined it as a company that uses live organisms such as bacteria, or enzymes to manufacture drugs for us. pharma companies are companies that use chemicals or you know, artificial materials to create ducks. But that definition has kind of gone out the window right now, because biologics do constitute majority of the portfolio of any pharma company that you see Case in point, k Trudeau is, which is a checkpoint inhibitor. It's an anti PD one antibody that has revolutionised the field of cancer treatment. It is owned by Merck pharmaceuticals, and it's expected to bring about $15 billion in sales just in 2020 alone. So you know, that categorization of biotechs being biological companies and pharmaceutical companies being chemical companies has kind of become outdated now. biotechs and by startups are, you know, high risk ventures that always push the boundaries, whether it's developing new signs, or looking at issues from a pioneering perspective and bringing innovation into play. So biotechs have, you know, basically become the r&d sector of the modern biopharma industry and pharmaceutical companies kind of excel at commercialising these products and bringing them from bench to bedside through Phase One and two, three clinical trials and marketing it. Okay, so there's like a symbiotic relationship between biotech and pharma companies, where biotech is usually involved in the preclinical innovative aspects of bringing new therapies, and pharma companies are involved in bringing these therapies from bench to bedside. So what is a biotech startup is basically a hierarchy of venture, where perhaps, you know, most of the riskier and truly innovative experimental efforts are carried out. And the stage of the biotech startup is usually intimately connected with the funding that it has at the moment. So as you know, startups can't, you know, they have to seek funding throughout every phase of building a company from the formation of an idea to a possible listing of an IPO. And there are several different types of funding rounds that is open to a startup, which extends from pre seed funding to series A, B, C funding, and in some cases, to D and E funding. So you know, let's just go through what these different funding rounds mean. So pre seed funding is a first date of funding that startups have access to. So when you seek funding at the stage, most startups will only consist of a few team members, or sometimes just a founder of the company. So the focal point at this stage is the creation of the proof of concept or the prototype that you have. And the funding at the stage can help you hire people that can assist you in growing to the next stage of funding. And the people that usually invest in your company at the stage are usually incubators or angel investors. So after that, you have the seed round of funding, which you know, allows you to grow to the point where you can begin to raise additional funding through the most common forms of series A, B, and C funding, which you might have heard associated with biotech startups. So you know, the, the funding at the stage had the seed stage is designed to help startups to move past their initial state stages of concept development into product development. And, you know, in mass majority of instant instances, angel investors will provide funding during this round. But nowadays, venture capital firms are more and more involved in providing seed round investments. Okay. So next after that, you know, you have the series a funding, which you must have, you know, which you would have heard most associated with biotech startups. So series, a funding is focused almost entirely on showing that the product that you have, or the technology that you have developed will fit into the market, okay. The funding that you raise at the stage of your startup should be used to bring whatever business model you have to fruition. And the most common elements of growth during the stage involves actually developing the products. So at this stage is when venture capital firms get mostly involved because they are the main investors in a series a funding and the series a funding, investments can range anywhere from $10 million, to maybe 50 to $60 million. So that's a huge amount of money that comes in during series A. And then you have Series B funding, which is when your company has already proven market viability, and now it needs to expand. And that expansion can be through the types of employees that you want to hire. Or if you want to expand in areas of marketing or business development, or you want to expand into different market segments, meaning you want to go into different disease types, for example, right. And, you know, at the at the stage, venture capitalists that are involved in funding late stage startups, that's when they get involved at the stage in bringing together your Series B funding. And lastly, you have the series c funding. So the series c funding is primarily sought when a startup wants to take part in large scale expansions. And this means you want to move into new market you want to acquire, for example, and other early stage biotech, which you think would give you an edge over your competitors, or you want to expand into an international market, right? So once you reach series c funding your your company is set, right you have displayed You are a player in the field, you're here to stay. And typically there is a lot of VC firms or hedge funds that want to invest in your company at that stage because now you have proven yourself. And you know, you're not a risky investment. So that usually involves about, you know, anywhere between 50 to $100 million at that stage. So these are the different stages that a biotech startup you know, goes Through. And that is usually how you define a biotech startup. Have they achieved? series A, B, or C funding? So that's how, if that makes sense to you?